Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 regulated IL-2
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
PD-1 regulated IL-2 is a conditionally active immunocytokine developed by Good Therapeutics and acquired by Roche. It is designed to deliver potent interleukin-2 (IL-2) stimulation to T cells, with its activity specifically regulated by programmed cell death protein 1 (PD-1). This conditional activation aims to enhance anti-tumor immune responses within the tumor microenvironment while minimizing the systemic toxicity often associated with traditional IL-2 therapies. The drug is being developed as a next-generation immunotherapy for oncology.
- Other names
- PD-1-regulated IL-2 receptor agonist programPD1-regulated IL-2 receptor agonist programPD 1-regulated IL-2 receptor agonist programPD-1-regulated IL-2 programPD1-regulated IL-2 programPD 1-regulated IL-2 program
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL2RB (IL-2 receptor beta chain)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on PD-1 regulated IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 regulated IL-2.